Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Psychopharmacology (Berl). 2022 Sep 13;239(11):3539–3550. doi: 10.1007/s00213-022-06226-1

Figure 2. EGR3 in the mPFC regulates mechanical nociception.

Figure 2.

(a) Experimental timeline for EGR3 overexpression in the mPFC followed by nociceptive and locomotor behavior tests. (b) Anatomical placement of viral infection with AAV-cre in combination with AAV-DIO-EGR3 (referred to as AAV-EGR3) and representative image (10x) of AAV infection in the mPFC. (c) Percent maximal effect determined through Von Frey filament test for mechanical hyperalgesia at increasing doses of oxycodone in rats that were microinjected in the mPFC with AAV-GFP or AAV-EGR3. * represents significant differences between AAV-GFP and AAV-EGR3 in % maximal effect at 1 mg/kg dose (d) Experimental timeline for bilateral CYSP injections into the mPFC followed by nociceptive and locomotor behavior tests. (e) Percent maximal effect determined through Von Frey filament test for mechanical hyperalgesia at increasing doses of oxycodone in vehicle- and CYSP-microinjected rats. * represents significant differences between vehicle and CYSP in % maximal effect at 3.2 mg/kg dose EGR3 gene (f) and protein (g) expression in the mPFC in vehicle and CYSP-microinjected rats. * represents significant differences between vehicle and CYSP in EGR3 expression. All data are presented as means ± SEMs with statistical significance (*) at P < 0.05.